首页 工具
登录
购物车
NU6027

NU6027

产品编号 T6612   CAS 220036-08-8

NU6027 是一种有效的 ATR/CDK 抑制剂,抑制 CDK1/2、ATR 和 DNA-PK,Ki 为 2.5 μM/1.3 μM、0.4 μM 和 2.2 μM。它以 ATR 依赖性方式增强羟基脲和顺铂的细胞毒性。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
NU6027 Chemical Structure
NU6027, CAS 220036-08-8
规格 价格/CNY 货期 数量
1 mg ¥ 248 现货
2 mg ¥ 355 现货
5 mg ¥ 578 现货
10 mg ¥ 980 现货
25 mg ¥ 1,630 现货
50 mg ¥ 2,390 现货
100 mg ¥ 3,530 现货
500 mg ¥ 7,480 现货
1 g ¥ 9,820 现货
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
MG-132限时半价
重组蛋白限时优惠
产品目录号及名称: NU6027 (T6612)
点击图片重新获取验证码
选择批次  
纯度: 99.85%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.
靶点活性 CDK1:2.5 μM(Ki), ATR:0.4 μM(Ki), DNA-PK:2.2 μM(Ki), CDK2:1.3 μM(Ki)
体外活性 NU6027 is soaked into crystals of monomeric CDK2 and the structure refined to a resolution of 1.85 ?. NU6027 (100 μM) inhibits growth of human tumor cells with mean GI50 of 10 μM. NU6027 causes a reduction in the number of cells in S-phase but not G1 or G2/M in MCF7 cells. [1] NU6027 is a potent inhibitor of cellular ATR activity with IC50 of 6.7 μM in MCF7 cells and 2.8 μM in GM847KD cells, and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner. NU6027 (10 μM) inhibits CDK2-mediated pRbT821 by 42% and pCHK1S345 by 70%. NU6027 significantly potentiates sensitivity of cisplatin (1.4-fold at 4 μM and 8.7-fold at 10 μM), doxorubicin (1.3-fold at 4 μM and 2.5-fold at 10 μM), camptothecin (1.4-fold at 4 μM and 2-fold at 10 μM) and hydroxyurea (1.8-fold at 4 μM) aganist MCF7 cells. NU6027 also potentiates 2 gy IR in a concentration-dependent manner and the cytotoxicity of camptothecin and temozolomide (a DNA methylating agent) at concentrations above and below their LC50. NU6027 (10 μM) attenuates G2/M arrest following DNA damage, inhibits RAD51 focus formation and increases the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy but not the antimitotic, paclitaxel in MCF7 cells. NU6027 (4 μM) is synthetically lethal when DNA single-strand break repair is impaired either through poly(ADP-ribose) polymerase (PARP) inhibition or defects in XRCC1 in MCF7 cells. [3] NU6027 (4 μM) increases the proportion of cell in early apoptosis to 7.5% after 48 hours treatment in EM-C11 cells compared to 1.73% in untreated cells. NU6027 (10 μM) treatment reduces survival in XRCC1 deficient OVCAR-4 cells compared to proficient cells. NU6027 enhances cytotoxicity of cisplatin in XRCC1 deficient OVCAR-3 cells compared to XRCC1 proficient cells. NU6027 enhances Cisplatin induced DSB accumulation in XRCC1 deficient OVCAR-3 cells. [4]
激酶实验 Enzyme Inhibition Studies: Inhibition of cyclin B1/CDK1 is assayed using enzyme prepared from starfish oocytes. Inhibition of cyclinA3/CDK2 is determined using a similar assay and an assay buffer comprised of 50 mM Tris-HCl pH 7.5 containing 5 mM MgCl2. The final ATP concentration in both CDK assays is 12.5 μM, and the IC50 concentration for NU6027 is the concentration required to inhibit enzyme activity by 50% under the assay conditions used. To determine the Km for ATP for cyclin B1/CDK1 and cyclin A3/CDK2, and Ki values for NU6027, assays are performed in the absence of NU6027 and at two fixed NU6027 concentrations (5 μM and 10 μM), with ATP concentrations ranging from 6.25 μM to 800 μM. Data are fitted to the Michaelis?Menten equation using unweighted nonlinear least squares regression.
细胞实验 The growth inhibitory activity of the NU6027 is evaluated in the NCl in vitro cell line panel using the standard 48 hours exposure assay and NU6027 concentrations ranging from 10-9 to 10-4 M. Relationships between the profile of cell growth inhibition produced by NU6027 and that of standard anticancer agents, and the established CDK inhibitors olomoucine and flavopiridol, is investigated using the COMPARE algorithm. (Only for Reference)
分子量 251.29
分子式 C11H17N5O2
CAS No. 220036-08-8

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

H2O: < 1 mg/mL (insoluble or slightly soluble)

Ethanol: 3 mg/mL (11.93 mM)

DMSO: 47 mg/mL (187 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 3.9795 mL 19.8973 mL 39.7947 mL 99.4866 mL
5 mM 0.7959 mL 3.9795 mL 7.9589 mL 19.8973 mL
10 mM 0.3979 mL 1.9897 mL 3.9795 mL 9.9487 mL
DMSO 20 mM 0.199 mL 0.9949 mL 1.9897 mL 4.9743 mL
50 mM 0.0796 mL 0.3979 mL 0.7959 mL 1.9897 mL
100 mM 0.0398 mL 0.199 mL 0.3979 mL 0.9949 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Arris CE, et al. J Med Chem, 2000, 43(15), 2797-2804. 2. Charrier JD, et al. J Med Chem, 2011, 54(7), 2320-2330. 3. Peasland A, et al. Br J Cancer, 2011, 105(3), 372-381. 4. Sultana R, et al. PLoS One, 2013, 8(2), e57098.
CGK733 ATM Inhibitor-8 ETP-46464 Elimusertib hydrochloride(1876467-74-1 free base) Wortmannin NU 7026 Tuvusertib AZ31

相关化合物库

该产品包含在如下化合物库中:
抗癌活性化合物库 抑制剂库 抗肺癌化合物库 DNA 损伤和修复分子库 抗肥胖化合物库 抗抑郁症化合物库 氧化还原化合物库 抗癌细胞代谢库 抗前列腺癌化合物库 NO PAINS 化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

NU6027 220036-08-8 Cell Cycle/Checkpoint DNA Damage/DNA Repair PI3K/Akt/mTOR signaling ATM/ATR DNA-PK CDK inhibit NU 6027 Ataxia telangiectasia mutated Cyclin dependent kinase cytotoxicity Inhibitor CDK2 cisplatin hydroxyurea ATR CDK1 ATM and RAD3 related NU-6027 cancer inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼